AEO for Life Sciences: How Biopharma and MedTech Vendors Get Cited in AI Answers
By Michael Etheredge, VP of Product Development ·
A director of clinical operations at a mid-size biotech asks an AI assistant to shortlist vendors for a Phase II data management platform. The assistant names three companies, summarizes their validation posture, and estimates pricing. Your company isn't one of them — not because you're the wrong fit, but because nothing in your public footprint gave the model a confident answer to point to.
This is happening earlier in the buying process than most life sciences vendors realize, and it's happening whether or not anyone on your team is watching. Answer Engine Optimization (AEO) is the discipline of making sure that when it happens, your company is the answer — not a gap the AI fills with a competitor, an outdated press release, or a message-board guess.
How do life sciences buyers actually use AI to research vendors?
Scientific and clinical buyers already think in literature-review terms — compress a wide field of sources, then verify what matters. That habit transfers directly to how they now research vendors.
Gartner's 2026 survey of 645 B2B buyers found that 45% had used generative AI to gather vendor and product information during a purchase, and that these buyers typically draw on close to seven information sources before deciding. Tellingly, 69% said they now lean on sales reps specifically to validate what an AI tool already told them — which means the assistant has often framed the shortlist before your team is in the room at all.
The stakes are higher in life sciences than in most categories, for two reasons. First, the buying committee is scientifically trained to distrust unsourced claims, so AI answers that cite verifiable material carry outsized weight with them. Second, the cost of a wrong impression compounds: separate research on pharma AI citation share (5W, 2026) shows that citation rank and revenue rank frequently diverge — the companies AI names are the ones whose drugs or platforms people actively research online, not necessarily the market leaders. Visibility has to be earned; it isn't inherited from reputation alone.
The practical implication: if you don't know what AI assistants currently say about your company, you don't know what your buyers already believe before your first call.
Why regulated content still gets cited — the MLR reality
The instinct in life sciences marketing is that compliance review makes AEO impractical: MLR forecloses the direct, comparative language AI platforms tend to cite. That's only half true. It forecloses certain claims. It doesn't forbid clear structure — and structure is most of what AEO requires.
The distinction that matters:
- Product-performance claims stay inside approved language, with references, exactly as they do today.
- Process and educational content — how a validation audit works, what a decentralized trial workflow requires, how to evaluate a platform migration — carries minimal claim risk. This is also where most life sciences vendor sites are thinnest, and where AI visibility can move fastest.
Content that opens each section with a direct, referenced answer — rather than positioning language before the substance — tends to be both easier for retrieval systems to extract and easier for an MLR reviewer to approve. Unambiguous statements with visible sourcing are simpler to sign off on than mood copy. Getting standard descriptions of your company, platform, and regulatory posture through review once, then reusing them verbatim across every page and third-party profile, turns MLR from a bottleneck into a consistency engine — which is exactly what AI entity recognition needs anyway.
Applying the DRIFT Framework to vendor visibility
We built the DRIFT Framework to track how AI narrative can drift away from what a life sciences company actually said — originally for the investor-relations and disclosure context. The same five steps apply directly to buyer-facing vendor visibility, because the underlying problem is identical: AI is already forming an answer about you, sourced from whatever is publicly available, whether or not you've had any say in it.
Detect
Establish a baseline of how ChatGPT, Claude, Gemini, and Perplexity currently describe your company, platform, and category position, using the real evaluation-stage questions your buyers would ask.
Review Sources
Trace which public materials the models are actually drawing on — distributor listings, old press coverage, review sites, forum threads — including sources you don't control and may not know exist.
Identify Gaps
Surface where AI is naming competitors instead of you, fragmenting your identity across inconsistent product names, or filling in blanks with outdated or speculative material.
Fix Alignment
Prioritize the source-level and on-site corrections that close the largest gaps first: entity consistency, evaluation-stage content, structured data.
Track Continuously
Monitor citation share on a recurring cadence, with increased frequency around launches, new data, and conference or publication cycles.
This isn't a rebrand of generic AEO advice — it's the same rigor we already apply to narrative integrity during quiet periods, pointed at the moment your buyer opens a chat window instead of the moment your investor does.
Entity consistency for complex scientific products
Life sciences portfolios are unusually easy for AI to get wrong. The same platform or assay often carries an internal code name, a generic descriptor, and a post-acquisition rebrand — sometimes all three across different pages of your own site. When naming is inconsistent, retrieval systems split your authority across several weak identities instead of one strong one, and the model either drops you from the answer or, worse, blends your product with a competitor's.
The fix is unglamorous but effective:
- One canonical name, everywhere — site, LinkedIn, distributor listings, review platforms, conference materials. Retire legacy names with an explicit "formerly known as," not a silent swap.
- A definition block on every product page — what it is, what category it belongs to, who uses it, and what it is not. That last sentence does disproportionate work against AI conflating similar products.
- Structured data — Organization, Product, and Article schema, plus Person schema for named scientific authors, so machines aren't inferring your corporate structure from prose.
- A consistent third-party footprint — the directories and distributor pages AI retrieves from should carry your approved language, not a five-year-old paraphrase.
Where to start: a baseline citation check
You don't need a large program to find out where you stand. Run 20-30 real evaluation-stage questions your buyers would ask, across three assistants, and log who gets named. If your competitors — or a random forum thread — show up and you don't, that's a measurable, defensible gap.